Taiwanese startup JelloX Biotech Inc. has forged a collaboration with Mayo Clinic, USA, through a know-how agreement to enhance their 3D digital imaging and artificial intelligence (AI) analysis technology. This partnership aims to further develop and validate JelloX’s innovative 3D pathology imaging technology.
JelloX previously gained recognition in the fifth cohort of the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator. This flagship program supports early-stage medical device and healthcare technology companies by accelerating their market entry. JelloX’s advanced 3D pathology imaging, combined with AI for spatial analysis, is designed to support precision cancer diagnosis.
Traditional 2D imaging methods in cancer diagnosis often miss critical spatial relationships of tumor biomarkers and are subject to interpretive variability. JelloX’s 3D imaging technology offers an enhanced spatial context, providing a 3D view of tissue architecture. This approach aims to improve diagnostic accuracy and consistency, offering pathologists a more comprehensive diagnostic tool for cancer patients.
In addition to imaging, the same biopsy tissue can be further analyzed through genomic sequencing and proteomics, offering patients a complete spectrum of precision medicine.
Dr. Yen-Yin Lin, CEO and founder of JelloX, stated, "Our goal is to provide researchers and clinicians with more precise diagnostic tools and to support pharmaceutical companies in their quest to develop new drugs, ensuring patients receive the right treatment at the right time".
This collaboration between JelloX Biotech and Mayo Clinic marks a significant step towards advancing precision medicine and improving cancer diagnostics.